72605-86-8

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 2-chlorothiazole-5-carboxylate is employed as a crucial intermediate in the synthesis of drugs and agrochemicals. Its unique structural features and reactivity make it an indispensable component in the development of new pharmaceuticals with enhanced therapeutic properties.
Used in Organic Synthesis:
In the field of organic synthesis, methyl 2-chlorothiazole-5-carboxylate is used as a versatile building block for the creation of complex organic molecules. Its reactivity allows for the formation of various chemical bonds, facilitating the synthesis of a wide range of compounds with diverse applications.
Used in Drug Discovery Research:
Methyl 2-chlorothiazole-5-carboxylate plays a significant role in drug discovery research, where it is used to explore and develop new bioactive compounds with potential therapeutic applications. Its unique structure and reactivity contribute to the identification of novel drug candidates and the advancement of pharmaceutical innovation.

Upstream product

• 6633-61-0 methyl 2-aminothiazole-5-carboxylate 
• 726185-57-5 methyl 2-aminothiazole-5-carboxylate hydrochloride 
• 3034-52-4 2-chlorothiazole 
• 79-22-1 methyl chloroformate 

Downstream Products

• 1426899-84-4 2-(2-o-tolyl-chroman-6-yloxy)-thiazole-5-carboxylic acid methyl ester 
• 133972-64-2 methyl 2-phenylaminothiazole-5-carboxylate 
• 726185-68-8 2-piperazin-1-yl-thiazole-5-carboxylic acid methyl ester 
• 1245157-52-1 methyl 2-(6-(4-(2-benzoxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-formate 

Relevant academic research and scientific papers

Discovery of biaryl anthranilides as full agonists for the high affinity niacin receptor

Biaryl anthranilides are reported as potent and selective full agonists for the high affinity niacin receptor GPR109A. The SAR presented outlines approaches to reduce serum shift and both CYPCYP2C8 and CYP2C9 liabilities, while improving PK and maintainin

Niacin receptor agonists, compositions containing such compounds and methods of treatment

The present invention encompasses compounds of Formula I: as well as pharmaceutically acceptable salts and hydrates thereof, that are useful for treating atherosclerosis, dyslipidemias and the like. Pharmaceutical compositions and methods of use are also included.

Tyrosine kinase inhibitors

The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such

Carboxylic acids and the esters thereof, pharmaceutical compositions thereto and processes for the preparation thereof

The present invention relates to carboxylic acids and esters of general formula wherein Ar, R, R1, X1, X3, X4, Y and Y1 are defined as in claim 1, the tautomers, the diastereomers, the enantiomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof, as well as the use thereof for the production and purification of antibodies and as labelled compounds in RIA and ELISA assays and as diagnostic or analytical aids in neurotransmitter research.

7-Methoxy-5-oxo-5H-thiazolo[2,3-b]quinazoline-2-carboxylic acid

7-Methoxy-5-oxo-5H-thiazolo[2,3-b]quinazoline-2-carboxylic acid, useful as an antiallergic agent, and prepared by reaction of 5-methoxyanthranilic acid with methyl 2-chlorothiazole-5-carboxylate, and subsequent hydrolysis, is described.